Multivariate Analysis of Factors for Time to ≥0.5 × 109 ANC/L, Platelets ≥50 × 109/L, TRM, Acute GVHD, Relapse, Survival, and LFS
| . | 0/1 . | n . | β Koeff. . | OR . | CI . | P . |
|---|---|---|---|---|---|---|
| ANC ≥0.5 × 109/L | ||||||
| BM group v others | 45/56 | −1.7 | 0.18 | 0.07-0.46 | <.001 | |
| G-CSF, no/yes | 69/32 | −1.2 | 0.30 | 0.11-0.82 | .017 | |
| Platelets ≥50 × 109/L | ||||||
| BM + CD34 groups/PBSC | 45/31 | −1.6 | 0.20 | 0.07-0.58 | .003 | |
| Methotrexate, no/yes | 8/68 | 2.81 | 16.6 | 1.26-223.6 | .015 | |
| TRM | ||||||
| Acute GVHD 0-I/II-IV | 81/25 | 2.25 | 9.49 | 3.16-28.5 | <.001 | |
| Methotrexate, no/yes | 16/92 | −1.86 | 0.16 | 0.11-0.59 | .006 | |
| Acute GVHD II-IV | ||||||
| OKT3, no/yes | 88/20 | 2.54 | 12.70 | 3.46-46.50 | .0002 | |
| Age <30/≥30 yrs | 39/69 | 1.54 | 4.66 | 1.17-18.20 | .03 | |
| Donor CMV+, no/yes | 55/50 | 1.23 | 3.46 | 1.11-10.80 | .034 | |
| Relapse | ||||||
| Disease stage, low/high | 46/57 | 1.65 | 5.21 | 1.54-17.6 | .008 | |
| Chronic GVHD, no/yes | 48/45 | −1.47 | 0.23 | 0.07-0.75 | .015 | |
| Survival | ||||||
| Low risk/high risk | 46/57 | 1.50 | 4.48 | 1.6-12.9 | .005 | |
| CML/acute leukemia | 49/56 | 1.47 | 4.35 | 1.5-12.8 | .007 | |
| Age <35/≥35 yrs | 54/54 | 1.46 | 4.31 | 1.5-12.7 | .008 | |
| Acute GVHD 0-I/II-IV | 81/25 | 1.12 | 3.06 | 1.0-9.4 | .05 | |
| LFS | ||||||
| Low risk/high risk | 46/57 | 1.68 | 5.37 | 1.8-15.8 | .003 | |
| Chronic GVHD, no/yes | 48/45 | −1.10 | 0.33 | 0.12-0.96 | .04 |
| . | 0/1 . | n . | β Koeff. . | OR . | CI . | P . |
|---|---|---|---|---|---|---|
| ANC ≥0.5 × 109/L | ||||||
| BM group v others | 45/56 | −1.7 | 0.18 | 0.07-0.46 | <.001 | |
| G-CSF, no/yes | 69/32 | −1.2 | 0.30 | 0.11-0.82 | .017 | |
| Platelets ≥50 × 109/L | ||||||
| BM + CD34 groups/PBSC | 45/31 | −1.6 | 0.20 | 0.07-0.58 | .003 | |
| Methotrexate, no/yes | 8/68 | 2.81 | 16.6 | 1.26-223.6 | .015 | |
| TRM | ||||||
| Acute GVHD 0-I/II-IV | 81/25 | 2.25 | 9.49 | 3.16-28.5 | <.001 | |
| Methotrexate, no/yes | 16/92 | −1.86 | 0.16 | 0.11-0.59 | .006 | |
| Acute GVHD II-IV | ||||||
| OKT3, no/yes | 88/20 | 2.54 | 12.70 | 3.46-46.50 | .0002 | |
| Age <30/≥30 yrs | 39/69 | 1.54 | 4.66 | 1.17-18.20 | .03 | |
| Donor CMV+, no/yes | 55/50 | 1.23 | 3.46 | 1.11-10.80 | .034 | |
| Relapse | ||||||
| Disease stage, low/high | 46/57 | 1.65 | 5.21 | 1.54-17.6 | .008 | |
| Chronic GVHD, no/yes | 48/45 | −1.47 | 0.23 | 0.07-0.75 | .015 | |
| Survival | ||||||
| Low risk/high risk | 46/57 | 1.50 | 4.48 | 1.6-12.9 | .005 | |
| CML/acute leukemia | 49/56 | 1.47 | 4.35 | 1.5-12.8 | .007 | |
| Age <35/≥35 yrs | 54/54 | 1.46 | 4.31 | 1.5-12.7 | .008 | |
| Acute GVHD 0-I/II-IV | 81/25 | 1.12 | 3.06 | 1.0-9.4 | .05 | |
| LFS | ||||||
| Low risk/high risk | 46/57 | 1.68 | 5.37 | 1.8-15.8 | .003 | |
| Chronic GVHD, no/yes | 48/45 | −1.10 | 0.33 | 0.12-0.96 | .04 |
Abbreviations: n, number of patients; CMV+, cytomegalovirus seropositive; low risk, first remission and first chronic phase versus after these stages.